L
Linda Janisch
Researcher at University of Chicago
Publications - 66
Citations - 3998
Linda Janisch is an academic researcher from University of Chicago. The author has contributed to research in topics: Pharmacokinetics & Pembrolizumab. The author has an hindex of 24, co-authored 65 publications receiving 3624 citations. Previous affiliations of Linda Janisch include Research Triangle Park & NorthShore University HealthSystem.
Papers
More filters
Journal ArticleDOI
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
Federico Innocenti,Samir D. Undevia,Lalitha Iyer,Peixian Chen,Soma Das,Masha Kocherginsky,Theodore Karrison,Linda Janisch,Jacqueline Ramírez,Charles M. Rudin,Everett E. Vokes,Mark J. Ratain +11 more
TL;DR: UGT1A1 genotype and total bilirubin levels are strongly associated with severe neutropenia, and could be used to identify cancer patients predisposed to the severe toxicity of irinotecan.
Journal ArticleDOI
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Lalitha Iyer,Soma Das,Linda Janisch,Ming Wen,Jacqueline Ramírez,Theodore Karrison,Gini F. Fleming,Everett E. Vokes,Richard L. Schilsky,Mark J. Ratain +9 more
TL;DR: It is suggested that screening for UGT1A1*28 polymorphism may identify patients with lower SN-38 glucuronidation rates and greater susceptibility to irinotecan induced gastrointestinal and bone marrow toxicity.
Journal ArticleDOI
Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
Razelle Kurzrock,Steven I. Sherman,Douglas W. Ball,Arlene A. Forastiere,Roger B. Cohen,Ranee Mehra,David G. Pfister,Ezra E.W. Cohen,Linda Janisch,Forlisa Nauling,David S. Hong,Chaan S. Ng,Lei Ye,Robert F. Gagel,John W. Frye,Thomas Müller,Mark J. Ratain,Ravi Salgia +17 more
TL;DR: Cabozantinib has an acceptable safety profile and is active in MTC, and may provide clinical benefit by simultaneously targeting multiple pathways of importance in M TC, including MET, VEGFR2, and RET.
Journal ArticleDOI
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
Jason J. Luke,Jeffrey Lemons,Theodore Karrison,Sean P. Pitroda,J.M. Melotek,Yuanyuan Zha,Hania A. Al-Hallaq,Ainhoa Arina,Nikolai N. Khodarev,Linda Janisch,Paul J. Chang,Jyoti D. Patel,Gini F. Fleming,John W. Moroney,Manish R. Sharma,Julia White,Mark J. Ratain,Thomas F. Gajewski,Ralph R. Weichselbaum,Steven J. Chmura +19 more
TL;DR: In this paper, the safety of pembrolizumab with multisite Stereotactic Body Radiotherapy (SBRT) was evaluated in patients with metastatic solid tumors.
Journal ArticleDOI
Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer
Federico Innocenti,Richard L. Schilsky,Jacqueline Ramírez,Linda Janisch,Samir D. Undevia,Larry House,Soma Das,Kehua Wu,Michelle Turcich,Robert de Wilton Marsh,Theodore Karrison,Michael Maitland,Ravi Salgia,Mark J. Ratain +13 more
TL;DR: The UGT1A1*28 genotype can be used to individualize dosing of irinotecan and the effect of genotype-guided dosing on efficacy in patients receiving irinOTecan should be evaluated.